1. 'H' is not for hydroxychloroquine—'H' is for heparin: lack of efficacy of hydroxychloroquine and the role of heparin in COVID-19—preliminary data of a prospective and interventional study from Brazil
- Author
-
Renata de Oliveira Costa, Joyce Santos Nascimento, Cadiele Oliana Reichert, Adriana Pedroso Augusto da Costa, Maria Aparecida Pedrosa dos Santos, Alberto Macedo Soares, Carlos Eduardo Mendonça Tomé, Ricardo Leite Hayden, Cassiano Waldanski dos Santos, Bruno Barreiro, Amer Abdul Basset El-Khatib, Luís Alberto de Pádua Covas Lage, Juliana Pereira, and Mônica Mazzurana Benetti
- Subjects
COVID-19 ,Heparin ,Hydroxychloroquine ,Prognostic factors ,Outcomes ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background COVID-19 pandemic is the major public health problem in the world actually. It’s associated with high morbidity and mortality. To date, no therapeutic measure has a curative potential. Hydroxychloroquine (HCQ) is a drug with immunomodulatory properties that has demonstrated antiviral efficacy in in vitro experiments, with conflicting results in in vivo studies. Methods A single-center, prospective and interventional study, that evaluates the impact on mortality of the HCQ use in 154 patients hospitalized with COVID-19 in a Brazilian public hospital. The study also aims to determine prognostic factors that predict mortality, ICU admission and endotracheal intubation in this population. Results 154 patients diagnosed with COVID-19 confirmed by RT-PCR and hospitalized were included. There was a male predominance (87/154, 56.5%), median age 60 years and 88% (136/154) had comorbidities. Among these, 76% (117/154) were admitted to the ICU and 29.2% (45/154) experienced EOT. The OMR was 51.3% (79/154). There was no difference in mortality between patients treated with HCQ (N = 95) and non-HCQ (N = 59) (44.1% × 55.8%, p = 0.758). In univariate analysis, age ≥ 60 years (HR 3.62, p
- Published
- 2022
- Full Text
- View/download PDF